7 research outputs found

    A new revisability paradox

    Get PDF
    In a recent article, Mark Colyvan has criticized Jerrold Katz's attempt to show that Quinean holism is self-refuting. Katz argued that a Quinean epistemology incorporating a principle of the universal revisability of beliefs would have to hold that that and other principles of the system were both revisable and unrevisable. Colyvan rejects Katz's argument for failing to take into account the logic of belief revision. But granting the terms of debate laid down by Colyvan, the universal revisability principle still commits Quineans to holding that one belief is both revisable and unrevisable: the belief that some beliefs are revisabl

    Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients

    Get PDF
    Gaucher disease (GD) is the most common lysosomal storage disorder (LSD). Based on a deficient β-glucocerebrosidase it leads to an accumulation of glucosylceramide. Standard diagnostic procedures include measurement of enzyme activity, genetic testing as well as analysis of chitotriosidase and CCL18/PARC as biomarkers. Even though chitotriosidase is the most well-established biomarker in GD, it is not specific for GD. Furthermore, it may be false negative in a significant percentage of GD patients due to mutation. Additionally, chitotriosidase reflects the changes in the course of the disease belatedly. This further enhances the need for a reliable biomarker, especially for the monitoring of the disease and the impact of potential treatments.Here, we evaluated the sensitivity and specificity of the previously reported biomarker Glucosylsphingosine with regard to different control groups (healthy control vs. GD carriers vs. other LSDs).Only GD patients displayed elevated levels of Glucosylsphingosine higher than 12 ng/ml whereas the comparison controls groups revealed concentrations below the pathological cut-off, verifying the specificity of Glucosylsphingosine as a biomarker for GD. In addition, we evaluated the biomarker before and during enzyme replacement therapy (ERT) in 19 patients, demonstrating a decrease in Glucosylsphingosine over time with the most pronounced reduction within the first 6 months of ERT. Furthermore, our data reveals a correlation between the medical consequence of specific mutations and Glucosylsphingosine.In summary, Glucosylsphingosine is a very promising, reliable and specific biomarker for GD

    Internet Stocks: Value-Drivers, Market Irrationality, and Mispricing an Overview of the Emerging Empirical Research Evidence

    No full text
    corecore